In a strategic maneuver that reshapes pharmaceutical pricing dynamics, Pfizer has secured a three-year exemption from President Donald Trump’s threatened tariffs by committing to slash some drug prices by up to 85% and establishing direct sales channels to American consumers. This landmark agreement represents the latest example of Trump’s transactional approach to trade policy, using tariff threats as leverage to achieve domestic policy objectives while providing temporary relief to major corporations facing potential import duties.
read more
FinanceNews Article 
October 2, 2025 | 03:19
October 2, 2025 | 03:19
FinanceMarket Report October 1, 2025 | 21:42
October 1, 2025 | 21:42
FinanceMarket Report October 1, 2025 | 15:42
October 1, 2025 | 15:42
Pfizer
3 in Finance and 0 in Crypto last week
Pfizer Stock Surges 7% on Trump Pricing Deal, 33% Upside Seen
Pfizer shares surged nearly 7% in a single trading session, marking the pharmaceutical giant’s best performance in recent memory following a landmark pricing agreement with the Trump administration. Dubbed ‘TrumpRX,’ the deal has reignited Wall Street interest in the beaten-down stock, with analysts predicting up to 33% additional upside from current levels while maintaining an attractive 6.75% dividend yield that remains well-covered despite the recent rally.
read morePfizer Avoids Tariffs, Cuts Drug Prices in Trump Deal
In a landmark move that sent shockwaves through global pharmaceutical markets, Pfizer has secured a crucial agreement with the Trump administration to avoid tariffs by committing to lower drug prices for American consumers. The deal, which includes a massive $70 billion domestic investment pledge, represents a significant victory for the pharmaceutical giant and sets a new precedent for industry pricing strategies. With competitors Eli Lilly and Merck expected to follow suit, this development signals a fundamental shift in how pharmaceutical companies navigate trade policy while addressing public pressure over medication costs.
read moreStocks Decline as Investors Brace for Hawkish Fed Statement
U.S. equity futures fell as investors anticipated a hawkish statement from the Federal Reserve, with stocks and Treasury yields declining. Fed Chairman Jerome Powell’s messaging and a busy session of earnings and data releases are in focus, while overseas markets also showed mixed performance.
read moreStocks Drop Ahead of Fed Decision, Pfizer’s Tidvak Receives FDA Approval
U.S. futures were down ahead of the Federal Reserve’s interest rate decision. April marked the worst month for equities, with high-profile brands set to release quarterly earnings. Pfizer’s shares rose after FDA’s full approval of Tidvak for treating cervical cancer, and investors awaited the Fed’s interest-rate decision.
read moreStock Market Outlook: Earnings Reports and Fed Meeting in Focus
U.S. futures were down as major indexes head towards their worst month and April since 2022. The stock market saw a rally, with notable gains from Tesla, Apple, and Domino’s Pizza. Investors are eagerly awaiting earnings reports from various big-name brands, including McDonald’s, Eli Lilly, Amazon, Starbucks, and others. Additionally, economic data is anticipated as the Federal Reserve’s policy meeting commences.
read moreEarnings Reports and CEO Shake-Up: Key Highlights for Investors This Week
The S&P 500 and Nasdaq Composite had a strong week, with Big Tech names driving the gains. Earnings reports are exceeding expectations, and this week will see major corporate earnings, key labor data, and a Federal Reserve meeting. Paramount Global’s CEO faces potential removal, while advertising spending is rebounding, and Tesla achieves a milestone in China.
read moreWall Street Focus: Fed Interest Rate Decision, Jobs Data, and Earnings
The upcoming week on Wall Street will be dominated by the Federal Reserve’s interest rate decision, jobs data for April, and a slew of earnings reports from major companies including Amazon, Apple, Pfizer, Coca-Cola, McDonald’s, and Starbucks. Investors will closely monitor Fed Chairman Jerome Powell’s press conference for insights into the US central bank’s future monetary policy path, while also keeping an eye on economic data such as auto sales and ISM manufacturing. Additionally, the week will see the release of US trade deficit data for March, factory orders data, and the US employment report for April.
read moreA Busy Week Ahead: Key Earnings and Economic Updates Expected
The stock market is gearing up for a busy week with major companies like Apple, Amazon, Pfizer, and eBay set to report their earnings. The Federal Reserve’s policy meeting and a slew of economic data releases will also keep investors on their toes. Additionally, companies like Dell Technologies, Nvidia, and Walmart are showing positive momentum, adding to the anticipation in the market.
read moreBristol Myers Squibb Reports First-Quarter Revenue and Cost-Cutting Measures
Bristol Myers Squibb reported a first-quarter revenue that exceeded expectations, driven by strong sales of its blockbuster blood thinner Eliquis and several new drugs. However, the company swung to a quarterly loss due to one-time charges related to recent deals, leading to plans to cut costs by $1.5 billion by 2025 and lay off 2,200 employees this year. The company aims to reinvest the savings in drug development and prioritize investment in key drug brands while discontinuing some drug programs.
read more